ED
APLS

Exane Derivatives’s Apellis Pharmaceuticals APLS Stock Holding History

Exane Derivatives’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,589
Closed -$68.2K – 1047
2021
Q1 		$68.2K Buy
+1,589
New +$75.2K 0.02% 481

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Exane Derivatives's APLS Position: Q2 2021 in Review

Exane Derivatives sold out of Apellis Pharmaceuticals (APLS) in Q2 2021, closing a stake of 1,589 shares — an estimated $68.2K sold.

Exane Derivatives first reported a position in APLS in Q1 2021 and held it in 1 quarter. The position peaked at $68.2K in Q1 2021. 204 funds tracked by Wall St. Rank hold APLS as of Q2 2021.

  • Exane Derivatives reported no remaining Apellis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Exane Derivatives sold 1,589 Apellis Pharmaceuticals shares in Q2 2021, an estimated $68.2K.
  • Exane Derivatives first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Exane Derivatives's Apellis Pharmaceuticals position peaked at $68.2K in Q1 2021.
  • 204 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2021.

Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.